ArticleFrontiers in pediatrics2026
Adjunctive use of a concentrated phytodietary compound in the management of prolonged diarrhea in infants: evidence from a real-world study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to evaluate the adjunctive therapeutic efficacy and safety of a concentrated compound phytodietary supplement in the management of prolonged diarrhea in infants, using data derived from real-world clinical settings. Methods: This retrospective, observational study analyzed real-world clinical data from three tertiary hospitals. Medical records of infants aged 6-12 months diagnosed with prolonged diarrhea (duration >14 days) between January 2020 and August 2021 were reviewed. Infants who received standard therapy alone were assigned to the control group, while those who received standard therapy in combination with the phytodietary supplement comprised the intervention group. Therapeutic response was assessed after 7 days of treatment and categorized as cure, improvement, or ineffective. Results: A total of 505 infants met the inclusion criteria, with 242 infants in the intervention group and 263 in the control group. Baseline characteristics, including sex distribution, median age, and nutritional status, did not differ significantly between groups. At day 7, the intervention group demonstrated cure, improvement, and ineffective rates of 52.9%, 40.9%, and 6.2%, respectively, yielding an overall efficacy rate of 93.8%. In contrast, the control group exhibited rates of 10.3%, 63.9%, and 25.8%, respectively, with a total efficacy rate of 74.2% ( Conclusion: This real-world analysis suggests that the adjunctive use of a concentrated phytodietary supplement in infants with prolonged diarrhea may enhance therapeutic outcomes, including a significant reduction in diarrhea duration and improved nutritional status. Continued use following resolution of diarrhea may support the introduction of complementary foods and contribute to improved growth trajectories. These findings support the potential clinical utility of phytodietary supplementation as an adjunct to standard care in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.